Crossmark

The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2025.100849

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wang, Bihui https://orcid.org/0000-0002-1282-2875
Zhu, Yuejie

Ru, Zhenyu

Zhang, Yulian https://orcid.org/0009-0009-7988-4032
Yu, Mingkai https://orcid.org/0000-0001-6046-2846
Li, Pingfen

Zhang, Manli https://orcid.org/0009-0001-8964-2135
Ding, Jianbing https://orcid.org/0000-0001-5506-7665
Chen, Zhifang https://orcid.org/0009-0003-1621-5903
Funding

Funding for this research was provided by:

Xinjiang Medical University

National Natural Science Foundation of China (82460502)

National Natural Science Foundation of China (82160545)
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2025-12-10
More Information

This article is maintained by: Elsevier

Article Title: The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2025.100849

Content Type: article

Copyright: © 2025 HCFMUSP. Published by Elsevier España, S.L.U.